And then I work with a lot of pediatric patients, a lot of their parents report bullying at school, [they’re] not able to partake in certain activities like swimming or [other] athletic activities. And then they also can sleep through the night which, of course is going to affect their development and quality of life, and then apart from the disease itself, but management of the disease I think can really affect a person's quality of life. So, the application of topicals is just such a huge commitment…every day, morning and night having to take that time to apply a cream-based moisturizer, but then also typically prescription creams and ointments, just keeping up with that regimen can take a toll. And then the act of like putting on an ointment in the morning and then putting your clothes on, a lot of patients are just not comfortable, and they don't feel great during the day because of that as well. So, it can really, really take a toll on a patient's life.
Pilat: I would emphasize the psychosocial impact, often after we initiate treatment options for patients, they'll tell us, “I haven't been able to wear shorts in 20 to 30 years,” and that's consistent for both conditions. Or [they’ll tell us] “I can finally wear a black shirt to work again without having to worry about flaking and being embarrassed over that,” and while these things may seem minor to an average individual, they can certainly impact patients over time, very significantly from the psychosocial impact.
And then the only other thing that I would add as far as psoriasis goes, psoriatic arthritis is very common in patients with psoriasis—I think it's an outdated statistic at this point—I believe the most updated 1 we have is about 30% of patients will go on to eventually develop psoriatic arthritis after the cutaneous involvement of plaque psoriasis. Oftentimes, these patients will experience extreme joint pain and stiffness in the morning, which of course significantly impacts patients on a daily basis as well.
Pharmacy Times: How might the pharmacist collaborate with dermatologists, primary care physicians, etc. to treat these conditions in patients?
Pilat: So, we fall into a unique area being in the specialty pharmacy. We’re kind of acting as the liaisons between the dermatologist the insurance companies and actually getting the medication to the patient in the end. So, we're involved from the very beginning, we can assist with the appropriate selection of a biologic considering patient-specific factors, we're checking on prior authorization statuses for these medications, so thankfully, we do have a centralized PA department where we are so we're not as involved with the submission process. But we definitely assist with handling the outcome of the prior authorization, so whether it's approved, oftentimes, financial assistance comes into play here and we'll seek this from manufacturer copay cards or supplemental government programs, sometimes patient assistance programs through manufacturers as well. If the medication is denied, we're communicating that a dermatologist what options might we have to appeal the denial for the original biologic that was submitted, or maybe switching to a preferred medication on the formulary, whatever it might be, we're kind of talking through those different options with a dermatologist. And then once a patient starts the biologic, we’re contacting them to review the medication beforehand, which includes a thorough review of the dosing schedules, potential [adverse effects (AEs)] that we might encounter, storage parameters, and then other pearls about the medications themselves. After the patient is starting the biologic, we're frequently checking in with them for any [AEs] or if a medication is just simply not working well [enough] to control the patient's symptoms. We're communicating both [AEs] and efficacy over to the dermatologist to potentially expedite a sooner follow-up visit in the office for reevaluation and consideration of other options that we have.
As far as some other things that might be helpful for [pharmacists] to be aware of, I would probably [say] lab monitoring…especially with the psoriasis medications. I can say that we do that here with our own internal pharmacy, and I'm working very closely with the dermatology office. If it's going to an outside pharmacy that doesn't necessarily have access to our health system records and those lab results, that creates kind of a difficult situation there, so we're lucky to fall within the same health system as the dermatology office that we primarily work with.
I would say that those are mainly the areas in which we collaborate with the dermatologists. As far as primary care physicians, they might assist in the referral to a dermatologist. Once they get to a systemic option, or especially biologics, it's typically coming from the dermatologist and maybe not the pediatrician office or the primary care physician. I would say that that's primarily how we're collaborating with those individuals.